Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock Price Passes Above 200-Day Moving Average – Here’s What Happened

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)’s share price crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $46.53 and traded as high as $52.07. Global X Genomics & Biotechnology ETF shares last traded at $52.07, with a volume of 13,658 shares changing hands.

Global X Genomics & Biotechnology ETF Stock Performance

The stock’s fifty day moving average price is $47.20 and its 200 day moving average price is $46.57. The stock has a market cap of $58.32 million, a P/E ratio of -22.25 and a beta of 1.21.

Institutional Investors Weigh In On Global X Genomics & Biotechnology ETF

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE increased its stake in shares of Global X Genomics & Biotechnology ETF by 67.8% during the first quarter. Bank of America Corp DE now owns 119,795 shares of the company’s stock valued at $5,240,000 after purchasing an additional 48,394 shares in the last quarter. U.S. Capital Wealth Advisors LLC bought a new position in Global X Genomics & Biotechnology ETF during the 4th quarter valued at approximately $575,000. Sei Investments Co. increased its position in Global X Genomics & Biotechnology ETF by 110.4% during the 2nd quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock valued at $194,000 after buying an additional 12,105 shares in the last quarter. Jane Street Group LLC raised its stake in Global X Genomics & Biotechnology ETF by 7.7% during the first quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock valued at $1,143,000 after buying an additional 10,308 shares during the last quarter. Finally, Wealth Management Partners LLC purchased a new position in Global X Genomics & Biotechnology ETF during the first quarter valued at $244,000. Hedge funds and other institutional investors own 56.95% of the company’s stock.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.